Pre-hospital oxygen therapy and saturation variability in COVID-19 patients with and without glucose metabolism disorders: part of the COLOS Study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
20 08 2024
20 08 2024
Historique:
received:
25
11
2023
accepted:
14
08
2024
medline:
21
8
2024
pubmed:
21
8
2024
entrez:
20
8
2024
Statut:
epublish
Résumé
The COVID-19 pandemic has revealed that viruses can have multiple receptor properties, penetrating various tissues and causing mutations in various genes, thus promoting a range of metabolic disorders. The purpose of this study was to investigate the connection between three factors: diabetic status, pre-hospitalization oxygen therapy, and saturation levels, to the values of morphological, inflammatory, and biochemical parameters in the blood serum of COVID-19 patients. The study group consisted of 2139 patients, 1076 women (50.30%) and 1063 men (49.70%), with an average age of 63.73 ± 15.69 years. The population was divided into three groups based on a three-stage scale, taking into account patients with either type 2 diabetes/prediabetes (473 patients), those who received oxygen therapy before hospitalization, and those with a saturation value of below 95% (cut-off value). Among patients who did not receive pre-hospitalization oxygen therapy, those with diabetes and a SpO2 level < 95% had significantly higher levels of D-dimers, procalcitonin, albumin, lymphocytes, RDW-SD ≥ 47, potassium, creatinine, and troponin T when compared to diabetic patients with a SpO2 level ≥ 95%. Similarly, in the same group of patients without pre-hospitalization oxygen therapy, those without diabetes but with a SpO2 level < 95% showed significantly increased levels of IL-6, CRP, albumin, lymphocytes, RDW-SD ≥ 47, glucose, potassium, sodium, creatinine, and ALT, compared to patients without diabetes and with a SpO2 level ≥ 95%. The findings suggest that lower saturation levels may result in increased potassium and glucose levels in patients who did not receive any oxygen therapy before hospitalization due to COVID-19. It is hypothesized that this may be caused by damage to pancreatic β-cells by SARS-CoV-2, and disturbances in the potassium channel, leading to cell membrane depolarization and insulin secretion.
Identifiants
pubmed: 39164354
doi: 10.1038/s41598-024-70240-w
pii: 10.1038/s41598-024-70240-w
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19286Informations de copyright
© 2024. The Author(s).
Références
WHO Coronavirus (COVID-19) Dashboard _ WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.
Metrics, G.H. Global burden of 369 diseases and injuries in 204 countries and territories , 1990 – 2019 : a systematic analysis for the Global Burden of Disease Study 2019. (2020), 396, https://doi.org/10.1016/S0140-6736(20)30925-9 .
Kulcsar, K. A. et al. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight https://doi.org/10.1172/jci.insight.131774 (2019).
doi: 10.1172/jci.insight.131774
pubmed: 31550243
pmcid: 6824443
Hosseinzadeh Adli, A. & Baghban Rahimi, S. Comment on “COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality”. Biomed. Pharmacother. https://doi.org/10.1016/j.biopha.2022.113477 (2022).
doi: 10.1016/j.biopha.2022.113477
pubmed: 36076579
pmcid: 9340149
Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16, 442–449. https://doi.org/10.2174/1573399815666191024085838 (2019).
doi: 10.2174/1573399815666191024085838
Tharmarajah, E. et al. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression. J. Infection. 82(5), 178–185 (2021).
doi: 10.1016/j.jinf.2021.03.008
Rao, S., Lau, A. & Hon-Cheong, S. Exploring diseases/traits and blood proteins causally related to expression of ace2, the putative receptor of sars-cov-2: A mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care 43, 1416–1426. https://doi.org/10.2337/dc20-0643 (2020).
doi: 10.2337/dc20-0643
pubmed: 32430459
Roberts, J. et al. Why is COVID-19 more severe in patients with diabetes? The role of angiotensin-converting enzyme 2, endothelial dysfunction and the immunoinflammatory system. Front. Cardiovasc. Med. 3(7), 629933. https://doi.org/10.3389/fcvm.2020.629933 (2021).
doi: 10.3389/fcvm.2020.629933
Batlle, D., Soler, M. J. & Ye, M. ACE2 and diabetes: ACE of ACEs?. Diabetes. 59(12), 2994–2996. https://doi.org/10.2337/db10-1205 (2010).
doi: 10.2337/db10-1205
pubmed: 21115782
pmcid: 2992757
Fitzgerald, K. Furin protease: From SARS CoV-2 to anthrax, diabetes, and hypertension. Permanente J. 24, 16–17. https://doi.org/10.7812/TPP/20.187 (2020).
doi: 10.7812/TPP/20.187
Sotler, T. & Šebeštjen, M. PCSK9 as an atherothrombotic risk factor. Int. J. Molecular Sci. https://doi.org/10.3390/ijms24031966 (2023).
doi: 10.3390/ijms24031966
Chen, Z., Wang, B., Mao, S. & Ye, Q. Assessment of global asymptomatic sars-cov-2 infection and management practices from China. Int. J. Biol. Sci. 17, 1119–1124. https://doi.org/10.7150/ijbs.59374 (2021).
doi: 10.7150/ijbs.59374
pubmed: 33867834
pmcid: 8040308
Mohamed, E. A. A. & Mohamed, K. S. A. Laboratory characteristics among patients with COVID-19: a single-center experience from Khartoum, Sudan. Af. Health Sci. 23, 16–22. https://doi.org/10.4314/ahs.v23i1.3 (2023).
doi: 10.4314/ahs.v23i1.3
Ertekin, B. & Acar, T. The relationship between prognosis and red cell distribution width (RDW) and RDW-albumin ratio (RAR) in patients with severe COVID-19 disease. Int. J. General Med. 15, 8637–8645. https://doi.org/10.2147/IJGM.S392453 (2022).
doi: 10.2147/IJGM.S392453
Clinical, W.H.O. Who, W. Clinical management of severe acute respiratory infection when novel coronavirus ( nCoV ) infection is suspected. 1–10. (2020).
Mak, J. K. L. & Kuja-halkola, R. Two years with COVID-19: The electronic frailty index identifies high-risk patients in the stockholm gerocovid study. Gerontology https://doi.org/10.1159/000527206 (2022).
doi: 10.1159/000527206
pubmed: 36450240
Lewandowski, Ł et al. Insulin and metformin administration: unravelling the multifaceted association with mortality across various clinical settings considering type 2 diabetes mellitus and COVID-19. Biomedicines 12, 605. https://doi.org/10.3390/biomedicines12030605 (2024).
doi: 10.3390/biomedicines12030605
pubmed: 38540218
pmcid: 10968012
Wang, C. et al. Red cell distribution width (RDW): A prognostic indicator of severe COVID-19. Ann. Transl. Med. 8, 1230–1230. https://doi.org/10.21037/atm-20-6090 (2020).
doi: 10.21037/atm-20-6090
pubmed: 33178762
pmcid: 7607068
Gong, J. et al. A tool for early prediction of severe coronavirus disease 2019 (COVID-19): A multicenter study using the risk nomogram in Wuhan and Guangdong, China. Clin. Infectious Diseases 71(15), 833–840 (2020).
doi: 10.1093/cid/ciaa443
Lorente, L. et al. Association between red blood cell distribution width and mortality of COVID-19 patients. Anaesth. Critical Care Pain Med. https://doi.org/10.1016/j.accpm.2020.10.013 (2021).
doi: 10.1016/j.accpm.2020.10.013
Sharma, D. et al. To study the role of absolute lymphocyte count and RDW in COVID 19 patients and their association with appearance of symptoms and severity. J. Ass. Phys. India 68, 39–42 (2020).
Eylul, P. et al. Anemia and iron metabolism in COVID - 19: A systematic review and meta - analysis. Eur. J. Epidemiol. 35, 763–773. https://doi.org/10.1007/s10654-020-00678-5 (2020).
doi: 10.1007/s10654-020-00678-5
Qu, R. et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J. Med. Virol. 92(9), 1533–1541. https://doi.org/10.1002/jmv.25767 (2020).
doi: 10.1002/jmv.25767
pubmed: 32181903
pmcid: 7228291
Pouladzadeh, M., Safdarian, M., Choghakabodi, P. M., Amini, F. & Sokooti, A. Validation of red cell distribution width as a COVID-19 severity screening tool. Future Sci. OA https://doi.org/10.2144/fsoa-2020-0199 (2021).
doi: 10.2144/fsoa-2020-0199
pubmed: 34254030
pmcid: 8056748
Lima-Martínez, M. M., Carrera Boada, C., Madera-Silva, M. D., Marín, W. & Contreras, M. COVID-19 and diabetes: A bidirectional relationship. Clinica e Investigacion en Arteriosclerosis 33, 151–157. https://doi.org/10.1016/j.arteri.2020.10.001 (2021).
doi: 10.1016/j.arteri.2020.10.001
pubmed: 33303218
Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann. Int. Med. 173, 268–277. https://doi.org/10.7326/M20-2003 (2020).
doi: 10.7326/M20-2003
pubmed: 32374815
Baroiu, L. et al. The role of D-dimers in the initial evaluation of COVID-19 [Response To Letter]. Therapeutics Clin. Risk Manage. 18, 593–594. https://doi.org/10.2147/TCRM.S373236 (2022).
doi: 10.2147/TCRM.S373236
Coomes, E. A. & Haghbayan, H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev. Med. Virol. 30, 1–9. https://doi.org/10.1002/rmv.2141 (2020).
doi: 10.1002/rmv.2141
pubmed: 32845568
Pepys, M. B. C-reactive protein predicts outcome in COVID-19: Is it also a therapeutic target?. Eur. Heart J. 42, 2280–2283. https://doi.org/10.1093/eurheartj/ehab169 (2021).
doi: 10.1093/eurheartj/ehab169
pubmed: 33778886
pmcid: 8083631
Johnson, A. S. & Winlow, W. COVID-19 vulnerabilities are intensified by declining human serum albumin levels. Exp. Physiol. 107, 674–682. https://doi.org/10.1113/EP089703 (2022).
doi: 10.1113/EP089703
pubmed: 34275164
Tchirikov, M. et al. Mid-trimester preterm premature rupture of membranes (PPROM): Etiology, diagnosis, classification, international recommendations of treatment options and outcome. J. Perinatal Med. 46, 465–488. https://doi.org/10.1515/jpm-2017-0027 (2018).
doi: 10.1515/jpm-2017-0027
Gao, Y. D. et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 76(2), 428–455. https://doi.org/10.1111/all.14657 (2021).
doi: 10.1111/all.14657
pubmed: 33185910
Zhu, H. et al. Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection. J. Clin. Lab. Anal. 34, 979–997. https://doi.org/10.1002/jcla.23392 (2020).
doi: 10.1002/jcla.23392
Masana, L. et al. Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 11, 1–9. https://doi.org/10.1038/s41598-021-86747-5 (2021).
doi: 10.1038/s41598-021-86747-5
Zhang, Y. et al. Influence of biotin intervention on glycemic control and lipid profile in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Front. Nutrition https://doi.org/10.3389/fnut.2022.1046800 (2022).
doi: 10.3389/fnut.2022.1046800
Wei, X. et al. Hypolipidemia is associated with the severity of COVID-19. J. Clin. Lipidol. 14, 297–304 (2020).
doi: 10.1016/j.jacl.2020.04.008
pubmed: 32430154
pmcid: 7192140
Baroiu, L. et al. COVID-19 impact on the liver. World J. Clin. Cases 9, 3814–3825. https://doi.org/10.12998/wjcc.v9.i16.3814 (2021).
doi: 10.12998/wjcc.v9.i16.3814
pubmed: 34141738
pmcid: 8180204
Ke, A., Zhou, J., Shi, G., Fang, N., Fan, J., Cai, J., Fan, J. & Lan, F. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. Biorxiv (2020).
Ponti, G., Maccaferri, M., Ruini, C., Tomasi, A. & Ozben, T. Biomarkers associated with COVID-19 disease progression. Cri. Rev. Clin. Lab. Sci. https://doi.org/10.1080/10408363.2020.1770685 (2020).
doi: 10.1080/10408363.2020.1770685
Henry, B. M., Helena, M., De Oliveira, S. & Benoit, S. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 ( COVID-19): A meta-analysis. Clin. Chem. Lab. Med. 58, 1021–1028 (2020).
doi: 10.1515/cclm-2020-0369
pubmed: 32286245
Phipps, M. M. et al. Acute liver injury in COVID-19: Prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology 72, 807–817. https://doi.org/10.1002/hep.31404 (2020).
doi: 10.1002/hep.31404
pubmed: 32473607
Fix, O. K. et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology 72, 287–304. https://doi.org/10.1002/hep.31281 (2020).
doi: 10.1002/hep.31281
pubmed: 32298473
Wang, Y., Lu, F. & Zhao, J. Reply to: Correspondence relating to “SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19”. J. Hepatol. 73, 996–998. https://doi.org/10.1016/j.jhep.2020.06.028 (2020).
doi: 10.1016/j.jhep.2020.06.028
pubmed: 32589896
pmcid: 7309894
Izcovich, A. et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One 15, 1–30. https://doi.org/10.1371/journal.pone.0241955 (2020).
doi: 10.1371/journal.pone.0241955
Słomczy, A., Wojnicz, P., Zatyka, P., Abramczyk, U. & Nowaczy, M. Consequences of COVID-19 for the pancreas. Int. J. Molecular Sci. 23(2), 864 (2022).
doi: 10.3390/ijms23020864
Cure, E. C. M. C. COVID - 19 may affect the endocrine pancreas by activating Na + / H + exchanger 2 and increasing lactate levels. J. Endocrinol. Investig. 43, 1167–1168. https://doi.org/10.1007/s40618-020-01307-4 (2020).
doi: 10.1007/s40618-020-01307-4
Noori, M., Aria, S., Sullman, M. J. M. & Chahhoud, K. C. How SARS - CoV - 2 might affect potassium balance via impairing epithelial sodium channels ?. Molecular Biol. Rep. 48, 6655–6661. https://doi.org/10.1007/s11033-021-06642-0 (2021).
doi: 10.1007/s11033-021-06642-0
Lord, K. & De León, D. D. Monogenic hyperinsulinemic hypoglycemia: Current insights into the pathogenesis and management. Int. J. Pediatric Endocrinol. 2013, 1–9. https://doi.org/10.1186/1687-9856-2013-3 (2013).
doi: 10.1186/1687-9856-2013-3